ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Ex vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionImmunotherapy targeting amyloid beta (Aβ) is limited by amyloid-related imaging abnormalities (ARIA), hypothesized to result from the direct binding of anti-Aβ monoclonal antibodies (mAbs) to vascular cerebral amyloid angiopathy (CAA), eliciting an immune response.
methodsImmunofluorescent staining was used to characterize ex vivo plaque and vascular binding of recombinant FDA-approved lecanemab and clinical candidate sabirnetug (ACU193) in 30 min and 24 h fixed APP:hE4 mouse brain tissue.
resultsFixation time was a key factor influencing Aβ antigen labeling with prolonged fixation differentially affecting pan-Aβ and mAb immunoreactivity. Compared with ACU193, lecanemab showed greater cortical plaque and cerebellar vascular labeling and encompassed a larger fraction of total pan-Aβ and β-pleated-sheet-rich signal, reflecting both mAb target abundance and selectivity. DISCUSSION: These findings emphasize that experimental protocols and antibody properties jointly shape the observed mAb binding patterns and highlight differences that may contribute to antibody-specific ARIA risk observed clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.